Top 5 Posters from DERM 2025 NP/PA Conference

At the Dermatology Education Foundation (DERM) 2025 NP/PA CME Conference, held in Las Vegas, Nevada, an array of different studies was highlighted in the HCPLive team’s coverage of the meeting.

A variety of disease states were spotlighted among these recent data, including alopecia areata, atopic dermatitis, psoriasis, and cutaneous lupus. The posters included findings on new medications such as ritlecitinib, deuruxolitinib, deucravacitinib, and more at DERM 2025. The following list includes 5 such posters from the conference:

1. Phase 3 Findings on Long-Term Ritlecitinib in Adults, Adolescents with Alopecia Areata

In 1 poster highlighted during the meeting, phase 3 findings from the ongoing ALLEGRO-LT study indicated that ritlecitinib 50 mg is effective in adults and adolescents aged 12 years and older living with alopecia areata as a long-term therapy. These 3-year results from the ALLEGRO-LT study were authored by Maryanne Makredes Senna, MD, a board-certified dermatologist for Beth Israel Lahey Health and an assistant professor of dermatology at Harvard Medical School.

Senna and coauthors noted in their research background that alopecia areata is an autoimmune disease that can often lead to patchy or complete non-scarring hair loss. Ritlecitinib, they expressed, is designed as a selective dual Janus kinase 3 (JAK3)/tyrosine kinase expressed in hepatocellular carcinoma (TEC) kinase family inhibitor.

2. Adults with Severe Alopecia Improve Anxiety, Depression with Deuruxolitinib Use

Additional findings by such investigators as Arash Mostaghimi, MD, MBA, MPH, an Associate Professor of Dermatology for Brigham and Women’s Hospital, demonstrated that deuruxolitinib significantly improved patients’ symptoms of anxiety and depression symptoms in those with severe alopecia areata, enhancing quality of life ratings.

These data from the THRIVE-AA1 and THRIVE-AA2 trials showed deuruxolitinib's efficacy in mental health outcomes, with Mostaghimi et al implementing the Hospital Anxiety and Depression Scale. Those on deuruxolitinib 8 mg BID demonstrated greater reductions in HADS scores versus those on a placebo, suggesting mental health benefits.

3. Patients with Atopic Dermatitis with High Itch, Low BSA Improve with Lebrikizumab

Another poster presented during DERM 2025 showed that a subpopulation of individuals living with atopic dermatitis who also had low levels of body surface area (BSA) involvement and high levels of itch saw positive results following lebrikizumab therapy, with significant disease control and positive itch impacts being highlighted.

These data were authored by investigators such as Shawn Kwatra, MD, a Joseph Warren Burnett Professor of Dermatology at the University of Maryland School of Medicine. These data were drawn from the ADvocate 1 and 2 studies, a set of 52-week, randomized, double-blind, placebo-controlled phase 3 trials evaluating lebrikizumab in atopic dermatitis.

4. Deucravacitinib Effective in Patients with Cutaneous Lupus, Including Concurrent SLE

Deucravacitinib therapy was also shown to be a potentially promising medication option for those with cutaneous lupus, including in patients with concurrent subacute cutaneous lupus erythematosus (SCLE). These data were drawn from the PAISLEY CLE trial, whose investigators looked into the efficacy and safety of deucravacitinib in those with discoid lupus erythematosus (DLE) and/or SCLE.

The phase 2, randomized, placebo-controlled, double-blind study was authored by investigators such as Victoria P. Werth, MD, a Professor of Dermatology at the Hospital of the University of Pennsylvania and the Veterans' Administration Medical Center. Werth and coauthors designed their research intending to assess deucravacitinib, a first-in-class, oral, selective allosteric inhibitor of tyrosine kinase 2 (TYK2).

5. Patient-Reported Hair Satisfaction with Deuruxolitinib for Severe Alopecia Areata

In another DERM 2025 poster, a post-hoc pooled analysis of the phase 3 THRIVE-AA1 and THRIVE-AA2 studies suggested that the vast majority of patients with severe alopecia areata and significant levels of hair regrowth on deuruxolitinib 8 mg BID changed their self-reported ratings from initial dissatisfaction to satisfaction with scalp hair results by the 24-week mark.

Paradi Mirmirani, MD, from the Permanente Medical Group’s Department of Dermatology in Vallejo, California, led a team of investigators in authoring this poster data. Mirmirani et al’s pooled analysis of THRIVE-AA1 and THRIVE-AA2 was designed to assess changes in patient-perceived satisfaction levels with scalp hair via the 5-point Hair Satisfaction Patient Reported Outcome (SPRO) scale.

For more from DERM 2025, view the latest conference coverage.

References

1. Senna M, Figueras I, Tran H, et al. Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata (AA): 3-Year Results from the ALLEGRO-LT Phase 3, Open-Label Study. Poster presented at the DERM 2025 NP/PA CME Conference; July 23 - 26, 2025; Las Vegas, Nevada.

2. Mostaghimi A, King B, Cassella J, et al. Improvement in Anxiety and Depression in Adult Patients with Severe Alopecia Areata Treated with Deuruxolitinib: Pooled Data from the THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials. Poster presented at the DERM 2025 NP/PA CME Conference; July 23 - 26, 2025; Las Vegas, Nevada.

3. Kwatra S, Werfel T, Mayo T, et al. Lebrikizumab Improves Atopic Dermatitis in Patients with Limited Skin Involvement and High Itch. Poster presented at the DERM 2025 NP/PA CME Conference; July 23 - 26, 2025; Las Vegas, Nevada.

4. Werth V, Gottlieb A, Merola J, et al. Efficacy and Safety of Deucravacitinib in Patients With Discoid Lupus Erythematosus (DLE) and/or Subacute Cutaneous Lupus Erythematosus (SCLE): Results From PAISLEY CLE, a Global, Phase 2 Randomized, Double-blind, Placebo-Controlled Trial. Presented at DERM 2025 NP PA CME Conference; July 23-26, 2025; Las Vegas, Nevada.

5. Mirmirani P, Mesinkovska N, Cassella J, et al. Change in Patient-Reported Hair Satisfaction During Deuruxolitinib Treatment of Severe Alopecia Areata: Pooled Data from the Phase 3 THRIVE-AA1 and THRIVE-AA2 Trials. Poster presented at the DERM 2025 NP/PA CME Conference; July 23 - 26, 2025; Las Vegas, Nevada.